There are limited options for treatment with cytotoxic regimens as prostate cancer is a highly chemoresistant malignancy.1 Currently, TBR plays a major role in the treatment of metastatic prostate cancer. Although this cytotoxic agent has been demonstrated to improve OS, it is associated with several difficulties such as dose-dependent adverse reactions, CT resistance and no response to treatment.1,2,11